INSM1, a novel biomarker for detection of neuroendocrine neoplasms: Cytopathologists’ view

40Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Background: Insulinoma-associated protein 1 (INSM1) has been considered as a novel immunostain for neuroendocrine tumors (NETs) and is hypothesized to be more reliable than first-generation NET biomarkers, such as CGA (chromogranin A), SYP (synaptophysin) and CD56 (neural cell adhesion molecule). In this review, we summarize existing literature on INSM1′ s reliability as an immunostain for detection of various NETs, its results in comparison to first-generation NET biomarkers, and its expression in both non-NETs and benign tissues/cells on cytology specimens (cell blocks/smears).

Cite

CITATION STYLE

APA

Maleki, Z., Nadella, A., Nadella, M., Patel, G., Patel, S., & Kholová, I. (2021, December 1). INSM1, a novel biomarker for detection of neuroendocrine neoplasms: Cytopathologists’ view. Diagnostics. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/diagnostics11122172

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free